Humacyte shareholders approve authorized shares increase to 350M, elect directors

Humacyte, Inc.

Authorized common shares raised from 250M to 350M; vote 82.6M for, 14.1M against.
Four Class I directors elected: Dougan, Green, Seimetz, Wallace (each with >56M votes).
PwC ratified as auditor for FY2025 (95.3M for, 2.0M against, 0.6M abstain).
Annual meeting quorum 63.1% (97.9M of 155.1M shares outstanding present).

item 5.03 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Humacyte, Inc.: Increased authorized shares of common stock from 250,000,000 to 350,000,000 (effective 2025-06-10).

Change: charter amendment
Effective: 2025-06-10

Exact text from the filing

At the Annual Meeting, upon the recommendation of the Company’s board of directors, the Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 250,000,000 to 350,000,000 (the “Amendment”). The Amendment became effective upon the filing thereof with the Secretary of State of the State of Delaware on June 10, 2025.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-25-000080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.